SS
AKBA icon

SBI Securities’s Akebia Therapeutics AKBA Stock Holding History

SBI Securities’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$6.31K Hold
4,539
– – ﹤0.01% 1933
2025
Q4 		$7.31K Sell
4,539
-14
-0.3% -$29 ﹤0.01% 1867
2025
Q3 		$12.4K Sell
4,553
-2,986
-40% -$9.93K ﹤0.01% 1662
2025
Q2 		$27.4K Sell
7,539
-94
-1% -$258 ﹤0.01% 1288
2025
Q1 		$14.7K Buy
7,633
+4,500
+144% +$9.19K ﹤0.01% 1448
2024
Q4 		$5.95K Buy
+3,133
New +$5.44K ﹤0.01% 1859

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

SBI Securities's AKBA Position: Q1 2026 in Review

SBI Securities held its Akebia Therapeutics (AKBA) position steady in Q1 2026 at 4,539 shares worth $6.31K. The position accounts for ﹤0.01% of the portfolio, ranked #1933.

SBI Securities first reported a position in AKBA in Q4 2024 and has held it in 6 quarters since. The position peaked at $27.4K in Q2 2025. 171 funds tracked by Wall St. Rank hold AKBA as of Q1 2026.

  • SBI Securities held 4,539 shares of Akebia Therapeutics worth $6.31K as of Q1 2026.
  • SBI Securities left its Akebia Therapeutics share count unchanged in Q1 2026.
  • Akebia Therapeutics made up ﹤0.01% of SBI Securities's portfolio in Q1 2026, its #1933 holding.
  • SBI Securities first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • SBI Securities's Akebia Therapeutics position peaked at $27.4K in Q2 2025.
  • 171 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q1 2026.

Based on SBI Securities's 13F filing for Q1 2026, filed 28 Apr 2026.